CEOLIVE Interviews CEO’s & Executives from publicly traded companies and start-ups.

Hemispherx Biopharma (HEB) Showing Strong Progress in Clinical Trials
April 30
CEO Interviews

In this episode of CEO Roadshow, we’re joined again by Mr. Thomas Equels, CEO of Hemispherx Biopharma, an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology.

Which ESports Stocks You Should Be Watching and Why?
April 01
CEO InterviewsCEOLIVE WatchlistCompany ProfilesTechnology Stocks

Esports is entering a tremendous growth phase. The global esports economy is expected to grow to more than $905 million this year, according to market research firm Newzoo. That figure would represent year-over-year growth of roughly 38%.

BriaCell Therapeutics (BCTXF) Presents Positive Efficacy Data with Lead Cancer Drug Candidate
December 14
CEO Interviews

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer.

Trimax Corp. (TMXN) Saavy Naturals Surpasses 200 Walmart Locations
December 13
CEO Interviews

Trimax Corporation, ticker TMXN and its wholly owned subsidiary Saavy Naturals announced today they have surpassed 200 Walmart locations for their luxurious handcrafted soaps which is a part of their Saavy Naturals Everyday brand.

CEOLIVE Profiles Up and Coming Innovative Companies

Quarterly Report Shows That Hemispherx Biopharma (NYSEMKT:HEB) Has a Unique Opportunity for Investors as it Continues to Make Strong Progress with Multiple Clinical Trials in 2019
May 21
Company ProfilesNewsNews

The total immuno-oncology market will be worth approximately $14 billion by 2019, rising to $34 billion by 2024, as the treatment of cancer patients undergoes drastic changes over the next decade, according to researchers.

Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma
May 13
Biotech StocksCompany Profiles

According to the latest news from the company, Roswell Park now has FDA authorization to proceed with its Phase 2 study investigating the effectiveness and safety of aspirin and Ampligen with or without interferon-alpha 2b (Intron A) compared to no drug treatments in a randomized three-arm study of patients with prostate cancer before undergoing radical prostatectomy.

Which ESports Stocks You Should Be Watching and Why?
April 01
CEO InterviewsCEOLIVE WatchlistCompany ProfilesTechnology Stocks

Esports is entering a tremendous growth phase. The global esports economy is expected to grow to more than $905 million this year, according to market research firm Newzoo. That figure would represent year-over-year growth of roughly 38%.

Login

Lost your password?